EGRX - Eagle Pharmaceuticals EPS misses by $0.27 misses on revenue

Eagle Pharmaceuticals (NASDAQ:EGRX): Q3 Non-GAAP EPS of $0.56 misses by $0.27; GAAP EPS of -$0.43 beats by $0.01. Revenue of $39.85M (-20.2% Y/Y) misses by $6.07M. Press Release “We are preparing for two significant product launches, vasopressin and PEMFEXY™, expected within the next ninety days that we believe will meaningfully increase the revenue and profitability of Eagle. With the recent licensing of CAL02 and landiolol, our expectation going forward is that we will utilize our cash and possibly the balance sheet to further strengthen the pipeline and portfolio,” stated Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals. R&D spend in 2021, on a non-GAAP basis, is expected to be $34-$38 million, as compared to $27.8 million in 2020. SG&A spend in 2021, on a non-GAAP basis, is expected to be $52-$56 million, as compared to $50.9 million in 2020.

For further details see:

Eagle Pharmaceuticals EPS misses by $0.27, misses on revenue